Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Current Liabilities (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Total Current Liabilities data on record, last reported at $28.6 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 9.34% year-over-year to $28.6 million; the TTM value through Dec 2025 reached $28.6 million, down 9.34%, while the annual FY2025 figure was $28.6 million, 9.34% down from the prior year.
  • Total Current Liabilities reached $28.6 million in Q4 2025 per ACRS's latest filing, up from $25.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $31.6 million in Q4 2024 and bottomed at $14.5 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $21.7 million, with a median of $20.8 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: crashed 31.31% in 2024, then soared 71.15% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $22.9 million in 2021, then decreased by 4.33% to $21.9 million in 2022, then skyrocketed by 41.09% to $31.0 million in 2023, then rose by 2.08% to $31.6 million in 2024, then fell by 9.34% to $28.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $28.6 million in Q4 2025, $25.6 million in Q3 2025, and $26.8 million in Q2 2025.